Evidence map›Paper›PMID 41136989›Full record

Trial reportBMC medicine2025

Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non-germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG).

Yi Xia, Yi Miao, Siqi Qian, Run Zhang, Shuchao Qin, Xiaoyan Xie, Bingzong Li, Yeqin Sha, Hanning Tang, Hui Jin and 6 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05200312 (A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, Zanubrutinib, in Combination With Lenalidomide Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05200312 phase2unknown statusnot on this map

A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, Zanubrutinib, in Combination With Lenalidomide Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

TypeinterventionalSponsorThe First Affiliated Hospital with Nanjing Medical UniversityRan2022 to 2025Enrolled36ConditionsNon Hodgkin Lymphoma, Diffuse Large B Cell LymphomaArmsZanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yi XiaDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China. cynthia0311@163.com.
Yi Miao *Department of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Siqi Qian *Department of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Run ZhangDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Shuchao QinDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Xiaoyan XieDepartment of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, 225000, China.
Bingzong LiDepartment of Hematology, the Second Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Yeqin ShaDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Hanning TangDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Hui JinDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Lei CaoDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Wei XuDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Lei FanDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China.
Jianyong LiDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China. lijianyonglm@163.com.
Wenyu ShiDepartment of Oncology, Affiliated Hospital of Nantong University, Nantong, 226001, China. shiwenyu@hotmail.com.
Huayuan ZhuDepartment of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210000, China. huayuan.zhu@hotmail.com.

Funding

China Postdoctoral Science Foundation 2021M691336Jiangsu Province Capability Improvement Project through Science, Technology and Education ZDXK202209Jiangsu Province Hospital Clinical Competence Improvement Project JSPH-MB-2022-19National Natural Science Foundation of China 82170166National Natural Science Foundation of China 82170186National Natural Science Foundation of China 82370193Postdoctoral Science Foundation of Jiangsu Province 2021K083AProject of National Key Clinical Specialty, Jiangsu Provincial Special Program of Medical Science BE2023775
6 · The paper itself

Abstract

backgroundPatients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) often exhibit suboptimal responses to standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy.

methodsThis multicenter, phase II study evaluated the safety and efficacy of zanubrutinib, lenalidomide, and R-CHOP (ZR2-CHOP) in newly diagnosed non-GCB DLBCL. Patients received oral zanubrutinib (160 mg twice daily), lenalidomide (25 mg once daily on Days 1-7), and standard R-CHOP every 21 days for up to six cycles.

resultsA total of 34 patients were enrolled. The median age was 55 years, with 29.4% over 60 years. Double-expressor lymphoma (DEL) was present in 64.7%, and 39.3% were classified as the MCD genetic subtype. The best overall response rate was 100%. Complete response (CR) was achieved in 70.6% of patients at mid-treatment and 94.1% at end-of-treatment. With a median follow-up of 28 months, the 2-year progression-free survival (PFS) rate was 84.8%, and the 2-year overall survival (OS) rate was 96.8%. In this small cohort, PFS benefit appeared consistent across high-risk subgroups, including those with DEL and MCD subtypes. Plasma ctDNA negativity was achieved in 84% (21/25) of evaluable patients during treatment. Grade 3-4 adverse events occurred in 67.6% of patients, primarily hematologic toxicities.

conclusionsZR2-CHOP demonstrated promising efficacy and manageable toxicity in newly diagnosed non-GCB DLBCL.

trial registrationClinicalTrials.gov Identifier: NCT05200312 (registered January 20, 2022).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLenalidomideLymphoma, Large B-Cell, DiffusePiperidinesPyrazolesPyrimidinesAdultAgedAged, 80 and overCyclophosphamideDoxorubicinFemaleHumansMaleMiddle AgedPrednisoneCyclophosphamideDoxorubicinLenalidomidePiperidinesPrednisonePyrazolesPyrimidinesRituximabVincristinezanubrutinibCtDNADLBCLLenalidomideNon-GCBZanubrutinib

Identifiers

PMID41136989
PMCPMC12553274

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.